The solution
Phase 1: 149 online quantitative interviews were conducted with migraine specialists treating both EM and CM patients prophylactically to understand their current usage, gauge their reactions to product profiles for both Product X and competing Product Y, and determine their intention to prescribe Product X in the future.
Phase 2: 31 qualitative interviews were conducted with payers and payer-advising KOLS to understand the varying treatment and access landscapes, clinical perceptions of Product X, expected HTA outcomes and pricing and reimbursement implications.
Markets: Canada, France, Germany, Italy, Spain, UK
The outcomes
-
Assess stakeholders perceived value of Product X based on the latest clinical trial results
-
Quantify the impact of revised end points and side effects on prescribing intent
-
Explore HCP preference for oral vs injection prophylactics
-
Compare Product X vs. Product Y by identifying strengths and weaknesses
-
Uncover anticipated Product X positioning relative to other treatments including novel mechanism of actions and other established agents
-
Assess the impact of new data on willingness to pay
-
Explore indication sequencing opportunities
-
Quantify the effect of EM only indication versus of CM and EM indication and made recommendations on impact of this for launch scenarios and pricing